GICS Sector : Healthcare
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome.The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
European Stocks That May Be Undervalued By Up To 49.4%
Jan -30
3 Global Stocks Possibly Trading Below Intrinsic Value Estimates In January 2026
Jan -30
European Market: 3 Stocks Conceivably Trading Below Estimated Value
Jan -30
European Value Stocks That May Be Priced Below Their Intrinsic Worth
Jan -21
Global Stocks Trading Below Estimated Intrinsic Values
Jan -21
3 European Stocks That May Be Trading Below Their Estimated Value By Up To 48.8%
Jan -21
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Oct -23
Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
Oct -09
Ryvu Therapeutics S.A.'s novel small molecule therapies drive 10.27% growth, fueled by increasing demand for targeted cancer treatments, advancements in precision medicine, and strategic partnerships. The company's innovative pipeline, strong R&D capabilities, and expanding presence in the oncology market also contribute to its rapid growth.
RYVU-001 is a small molecule inhibitor of the CDK9 kinase, a key regulator of transcriptional elongation, with potential to treat various types of cancer.
RYVU-002 is a small molecule inhibitor of the CDK7 kinase, a key regulator of transcriptional initiation, with potential to treat various types of cancer.
RYVU-003 is a small molecule inhibitor of the CDK12/13 kinases, key regulators of transcriptional elongation, with potential to treat various types of cancer.
Ryvu Therapeutics S.A. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Ryvu Therapeutics S.A. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Ryvu Therapeutics S.A. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, the suppliers still have some leverage due to the specialized nature of the products.
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. This limits the threat of new entrants to the market.
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Ryvu Therapeutics S.A. faces intense competition from companies with similar products and technologies.
| Value | |
|---|---|
| Debt Weight | 0.35% |
| Debt Cost | 6.92% |
| Equity Weight | 99.65% |
| Equity Cost | 6.92% |
| WACC | 6.92% |
| Leverage | 0.35% |
Value: 8.4
Growth: 6.8
Quality: 5.5
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.6
Growth: 6.1
Quality: 4.3
Yield: 0.0
Momentum: 7.0
Volatility: 0.0
1-Year Total Return ->
Value: 1.4
Growth: 3.9
Quality: 4.7
Yield: 1.2
Momentum: 9.0
Volatility: 2.3
1-Year Total Return ->
Value: 8.0
Growth: 4.8
Quality: 4.2
Yield: 0.0
Momentum: 4.5
Volatility: 0.0
1-Year Total Return ->
Value: 6.4
Growth: 4.0
Quality: 5.0
Yield: 0.0
Momentum: 4.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.0
Growth: 2.6
Quality: 3.0
Yield: 0.0
Momentum: 0.0
Volatility: 2.0
1-Year Total Return ->